Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Tempus, Elegen, Eurofins Viracor, Almaden Genomics, Enhanc3D

Tempus xT CDx

Tempus AI has launched the next-generation sequencing-based xT CDx test. The US Food and Drug Administration-approved test comprises 648 genes and is used to provide solid tumor profiling in cancer patients with solid malignant neoplasms. It detects single- and multi-nucleotide variants, insertions, and deletions and microsatellite instability status from formalin-fixed, paraffin-embedded tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens. The companion diagnostic test is intended to identify patients who may benefit from treatment with certain targeted therapies.


Elegen Enfinia Plasmid DNA

Elegen has launched Enfinia Plasmid DNA for clonal synthesis of high-complexity clonal genes up to 15 kb, verified by next-generation sequencing and shipped globally from Elegen's US facilities in 10 business days, compared to typical waits of several months for clonal synthesis of long and complex genes through existing services. Elegen also said that pricing will not exceed $.20/bp for standard-complexity sequences above 3 kb in length.


Eurofins Viracor Chagas Disease qPCR Test

Eurofins Viracor has launched a qPCR assay for Trypanosoma cruzi, the pathogen that causes Chagas disease. The test incorporates a preanalytical process designed to reduce testing delays and minimize instances of testing not performed, and the company said that it can provide results within 48 hours of sample receipt. The test supports early diagnosis and monitoring of Chagas disease, particularly in high-risk populations such as transplant recipients, where timely detection is critical to preventing disease progression or reactivation, the company said. The test has not been cleared or approved for diagnostic use by the US Food and Drug Administration.


Almaden Genomics G.nome 2.0

Almaden Genomics has launched G.nome 2.0, an upgrade to its data analysis platform G.nome. A key feature of the new software is the introduction of G.nome Analytics, which connects bioinformatics workflows directly to biologist-friendly analysis tools, enabling users to further explore their data through tertiary analysis and advanced visualizations, according to the company. The platform has also undergone a comprehensive user interface upgrade, incorporating improved tools for tracking, building, and running analysis workflows to make managing large-scale bioinformatics projects more seamless, the company said.


Enhanc3D Genomics Multiomics Products

Enhanc3D Genomics of Cambridge, UK, has launched a number of multiomics products for use in drug discovery. GenLinkConnect links GWAS SNP data to genes in specific cell types, pinpointing long-range interactions between regulatory elements and promoters. GenLinkResponse maps regulatory networks to uncover epigenetic and regulatory mechanisms that drive cell responses to treatment with compounds of interest. GenLinkProfile provides cell-specific profiling of regulatory elements and disease mechanisms, integrating 3D genomics interaction data with multiomics assays to obtain high-resolution contact maps and analyses of SNP-gene interactions. The new products are supported by Enhanc3D's visualization and data management software, GenLinkHub.


For more recently launched products and services, please visit the New Products page on our website.